Pricing Log in Create free account
Friday 6 November 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

172.71 4.23 +2.51%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Repligen Corporation (RGEN) valuation and DCF model

What the price implies · reverse DCF

At $172.71 the price implies free cash flow after share-based pay growing 31.1% a year for ten years.

Free cash flow after share-based pay grew 39.9% a year over the last ten years, 40.4% over the last five. The price asks for close to its ten-year rate. The industry’s median company is priced for 13.1%.

In December 2017 the price assumed 29.2% a year; Repligen Corporation went on to grow free cash flow after share-based pay 35.4% a year to FY2025.

Price implies
31.1%
Last 5 years, reported
40.4%
Last 10 years, reported
39.9%
Industry median implies
13.1%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
31.1% a year for ten years
$172.71
today’s price
Its base case
25.0% a year for five years, then 15.0%
$81.83
52.6% below today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Repligen Corporation’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 31.1% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Repligen Corporation’s own cost of capital: risk-free 4.3% + beta 1.12 × equity premium 4.5% = 9.3% cost of equity; weighted, 9.3%.

Use 9.3%
Equity value $4.63b ▼ below market cap $9.78b
Base case value per share $81.83 equity value ÷ 56.61m shares
Current price $172.71 market price per share
Below today’s price 52.6% downside at the base case’s assumptions

How we got there$1.39b 10 years of cash to equity+$2.93b terminal value+$307.38m net cash=$4.63b equity value÷56.61m shares=$81.83 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Medical Instruments & Supplies).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E — 157.07× 141.05× — 30.28× —
P/FCF 170.11× 142.08× 162.82× 4% above 23.49× 624% above
P/B 4.57× 4.56× 4.81× 5% below 2.34× 95% above
EV/EBITDA 60.12× 78.39× 72.09× 17% below 14.87× 304% above
EV/Sales 11.57× 12.55× 14.80× 22% below 2.75× 320% above
P/E P/FCF P/B EV/EBITDA EV/Sales
73.92×133.06×192.19×251.33×10Y avg 141.05×201620172018201920202021202220232025

P/E has no reading today; its 10-year average is 141.05×.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.